Mode
Text Size
Log in / Sign up
N/A N=376 Randomized Double-blind Other

Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease · COPD · Chronic Bronchitis · Emphysema

Enrolled (actual)
376
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcome: Primary: Effect of Intervention on Quality of Patient Clinician Communication About End-of-Life Care(QOC) Scale — 23.3; 19.2; 34.0; 25.5 units on a scale — p=0.03

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Audit and Feedback (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
May 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Effect of Intervention on Quality of Patient Clinician Communication About End-of-Life Care(QOC) Scale
23.3; 19.2; 34.0; 25.5 0.03 sig
SECONDARY
Effect of Intervention on Patient Reported Discussions About Treatment Preferences at Their Last Clinic Visit.
0.30; 0.11

Summary

The purpose of this study is to evaluate a multifaceted intervention to improve the quality of end-of-life communication between patients with COPD and their primary care providers using information about patients preferences for end of life care and how to communicate and use this information to activate patients, family members, and healthcare providers.

Eligibility Criteria

Inclusion Criteria

One or more of the following:

1 Have 3 or more outpatient clinics visits for COPD (ICD-9) in the two years prior to enrollment.

  • Have been hospitalized with a primary discharge diagnosis (ICD-9) for COPD in the two years prior to enrollment.
  • Active use of inhaled beta-agonist and ipratropium bromide (or equivalent in combination inhalers like Combivent) in the 12 months prior to enrollment.

Plus

  • Have a future visit scheduled in one of the eligible primary care or chest clinics; and
  • Have airflow limitation

Exclusion Criteria

  • If they have cognitive dysfunction, language barriers or severe psychiatric disorder that would preclude them from completing the questionnaires. This was assessed initially by the patients provider and by the research assistant during in-person interviews.
  • The provider taking care of their COPD does not participate.
  • Have a new diagnosis of COPD within the last month.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00106080). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search